Pancreatic duct stent preventing post endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients

Objective To evaluate the preventive effect of pancreatic duct stent against post endoscopic retrograde cholangiopancreatography(ERCP)pancreatitis(PEP)and hyperamylasemia in high-risk patients.Methods A total of 160 patients with high-risk PEP underwent ERCP therapy between Jan.2013 and Dec.2014 and were retrospectively analyzed.The patients were divided into pancreatic duct stent group(n=82)and control group(n=78)according to whether receiving pancreatic duct stent or not.Abdominal pain was evaluated after ERCP.The levels of serum amylase were detected at 3hand24 hafter ERCP.The incidences of PEP and hyperamylasemia were compared between the two groups.Results The serum amylase levels at 3hand 24 hafter ERCP in pancreatic duct stent group were significantly lower than those in control group([184.89±257.33]U/L vs [305.35±371.81]U/L,P0.05;[268.07±344.73]U/L vs [465.86±639.94]U/L,P0.05).The incidences of PEP and hyperamylasemia in pancreatic duct stent group were also significantly lower than those in control group(2.4% [2/82]vs 11.5% [9/78],P0.05;17.1% [14/82]vs 30.8% [24/78],P0.05).The incidence of abdominal pain and abdominal pain score were(19.5%[16/82],[1.24±0.58])in pancreatic duct stent group,which were significantly lower than those in control group(43.6% [34/78],[1.68±0.97])(P=0.001).Conclusion Pancreatic duct stent can effectively prevent PEP and hyperamylasemia in high-risk patients following ERCP.